STAT3 and neoplasm: The anti-tumor activity of napabucasin either by itself or in combination with conventional therapeutics has been demonstrated in several recent clinical trials24, strongly suggesting the potential of small-molecule STAT3 inhibitors in suppressing metastasis and preventing relapse in patients with varying cancer types by targeting CSCs.